Key facts
- This page summarizes Jonathan Rubin's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2023, 16:00.
Jonathan Rubin - 22 Feb 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Reporting relationship
- SVP, Chief Medical Officer
- Issuer ticker
- SUPN
- Reported as of
- 22 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2023, 16:00:52 UTC
- Prior SEC filing
- 21 Feb 2023
- Next SEC filing
- 27 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Rubin filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 24 Feb 2023.
Change
- Previous filing in this sequence was filed on 21 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SUPN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +750
- Change %
- +43%
- Price
- $0.000000
- Shares after
- 2,497
- Date
- 22 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SUPN
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- $0
- Shares
- -750
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 2,250
- Date
- 22 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 750
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Includes an aggregate of 247 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
Footnote F2
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
Footnote F3
These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023.